SAFETY AND EFFICACY OF HYDROXYUREA AS A PROPHYLACTIC THERAPY FOR SICKLE CELL

羟基脲作为镰状细胞预防疗法的安全性和有效性

• 批准号: 5217839
• 负责人: Eugene P Orringer
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5217839
• 关键词: blood disorder chemotherapy; clinical research; clinical trials; drug screening /evaluation; erythrocytes; hemoglobin F; human subject; human therapy evaluation; hydroxyurea; sickle cell anemia

The purpose of this double-blind, randomized study is: a) to compare the clinical course of patients receiving hydroxyurea to a control group receiving placebo and; b) to quantitate the effect of hydroxyurea on fetal hemoglobin production in the red blood cells of patients with sickle cell anemia.

这项双盲、随机研究的目的是：a) 比较 接受羟基脲治疗的患者与对照组的临床病程 接受安慰剂； b) 定量羟基脲对 患有以下疾病的患者红细胞中胎儿血红蛋白的产生 镰状细胞性贫血。